Related Experiment Video
Updated: Jun 29, 2025
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Optimal Medical Therapy for Stable Ischemic Heart Disease: Focus on Anti-anginal Therapy
Brett M Montelaro1, Rand Ibrahim1, Marc Thames2
1Division of Cardiology, Department of Medicine, J. Willis Hurst Internal Medicine Residency Training Program, Emory University School of Medicine, Atlanta, GA, USA.
Insights
Chronic coronary disease (CCD) management focuses on reducing exertional angina pectoris. Anti-anginal therapies improve the balance between heart blood supply and demand, minimizing chest discomfort.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic coronary disease (CCD) is a significant global health burden.
- Exertional angina pectoris, a common symptom of CCD, significantly impacts patient quality of life.
- Angina results from an imbalance between myocardial oxygen supply and demand.
Purpose of the Study:
- To describe the pathophysiologic basis of angina symptoms.
- To review current anti-anginal pharmacologic therapies.
- To explain how these therapies alleviate angina.
Main Methods:
- Literature review of pathophysiology of angina.
- Summary of current anti-anginal medication classes.
- Discussion of therapeutic mechanisms of action.
Main Results:
- Angina pathophysiology involves insufficient coronary blood flow to meet myocardial metabolic needs.
- Pharmacologic therapies, including beta-blockers, calcium channel blockers, nitrates, and ranolazine, are crucial for angina management.
- These medications work by optimizing the relationship between myocardial blood flow and metabolic demand.
Conclusions:
- Effective management of CCD and its symptoms, like angina, relies on lifestyle changes, risk factor modification, and pharmacologic interventions.
- Anti-anginal drugs play a vital role in preventing and minimizing angina episodes.
- Understanding the mechanisms of these therapies is key to improving patient outcomes.
Abstract:
Chronic coronary disease (CCD) is a major cause of morbidity and mortality worldwide. The most common symptom of CCD is exertional angina pectoris, a discomfort in the chest that commonly occurs during activities of daily life. Patients are dismayed by recurring episodes of angina and seek medical help in preventing or minimizing episodes. Angina occurs when the coronary arteries are unable to supply sufficient blood flow to the cardiac muscle to meet the metabolic needs of the left ventricular myocardium. While lifestyle changes and aggressive risk factor modification play a critical role in the management of CCD, management of angina usually requires pharmacologic therapy. Medications such as beta-blockers, calcium channel blockers, nitrates, ranolazine, and others ultimately work to improve the mismatch between myocardial blood flow and metabolic demand. This manuscript briefly describes the pathophysiologic basis for symptoms of angina, and how currently available anti-anginal therapies contribute to preventing or minimize the occurrence of angina.
More Related Videos
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:22Heart Failure Drugs: β-Blockers
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...